
UroGen Pharma (URGN) Stock Forecast & Price Target
UroGen Pharma (URGN) Analyst Ratings
Bulls say
UroGen Pharma Ltd has demonstrated strong financial performance with a projected increase in top-line sales from $114.1 million in 2025 to $338.8 million by 2026, reflecting robust growth in the company's revenue streams. The company reported a 9% year-over-year growth in net product revenue, achieving $90.4 million in full-year 2024, while Jelmyto revenue in Q4 2024 rose to $24.6 million, indicating a 15% increase in underlying demand. Furthermore, favorable clinical results from the Phase 3 ENVISION trial for UGN-102 indicate a substantial market opportunity exceeding $5 billion, positioning UroGen for potential transformative impact in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
Bears say
UroGen Pharma Ltd reported a significant full-year net loss of $126.9 million, translating to a loss of $2.96 per share, with a further projected net loss of $3.01 per diluted share, indicating ongoing financial challenges. Key risks contributing to a negative outlook include potential market penetration issues due to increased competition, potential failures in clinical trials, and the inability to secure market exclusivity for critical products, such as UGN-103 and UGN-104. Although the company recorded $24.6 million in fourth-quarter revenue, it represented a modest miss against expectations, while net losses in Q4 widened to $37.5 million compared to $26 million in the previous year, underscoring concerns about its long-term financial viability.
This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.
UroGen Pharma (URGN) Analyst Forecast & Price Prediction
Start investing in UroGen Pharma (URGN)
Order type
Buy in
Order amount
Est. shares
0 shares